retatrutide injection pen A New Obesity Drug Delivered Surgery-Level Weight Loss in Clinical Trials Reusable Injection Pen Dark Gray

The headline results, as released in the Eli Lilly investor communication and aligned with the study design paper by Giblin and colleagues published in Diabetes, Obesity and Metabolism in 2026, are unusually strong for a Phase 3 obesity trial: Retatrutide 12 mg: mean body-weight reduction of 28.7 percent, roughly 32.3 kg (about 71.2 lbs) from baseline

Sandoval and DAlessio (2015)

GLP-1 analoglar, zellikle tip 2 diyabet ve morbid obezite tedavisinde nemli faydalar salyor

A survey of 100,000 people by Numerator claims to have found that 47% of GLP-1 users take the drug for weight loss

The supplement supports gut health and metabolism with three clinically studied ingredients